AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Find an Eye MD near you!
- Details
Allergan announced it will develop and commercialize dry eye drug tavilermide through an exclusive licensing agreement with Mimetogen Pharmaceuticals.
- Details
Researchers have identified a steroid that has the potential to reverse cataracts by blocking α-crystallin aggregation.
- Details
Study finds that glaucoma patients are at higher risk for complications and show weaker visual improvement.
Read more: Cataract surgery in glaucoma patients: More risks, less benefit
- Details
AGTC has filed a new drug application with the FDA to conduct a clinical trial of a gene therapy product to treat achromatopsia.
- Details
Case report brings to light a potentially under-diagnosed cause of ocular neuropathic pain – vitamin B12 deficiency.
Read more: Ocular neuropathic pain linked to vitamin B12 deficiency
- Details
Literature review finds no evidence to support routine use of NSAIDs after cataract surgery to prevent vision loss from CME.
Read more: NSAIDs after cataract surgery don’t prevent long-term vision loss